BioWorld

March 1, 2002

Centocor’s Remicade Receives Third Rheumatoid Arthritis Nod

Centocor Inc.’s Remicade is inflating - both in uses and sales - having received a third approval in a rheumatoid arthritis indication. (BioWorld Today) Read More

FDA Panel Agrees To Corixa’s Melacine Phase III Study Protocol

How Mutated Tumor-Suppressor Gene May Influence Burgeoning Anti-Angiogenic Drug Treatment

Vasogen CHF Immune Therapy Succeeds In Phase II CHF Study

Other News To Note

Gen-Probe, Chiron Gain Approval For HIV, HCV Nucleic Acid Tests

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Dec. 15, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 16, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...